- Home
- AB vs PRAX Comparison
AB vs PRAX Comparison
Compare AB & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AB
- PRAX
- Stock Information
- Founded
- AB 1987
- PRAX 2015
- Country
- AB United States
- PRAX United States
- Employees
- AB N/A
- PRAX N/A
- Industry
- AB Investment Managers
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- AB Finance
- PRAX Health Care
- Exchange
- AB Nasdaq
- PRAX Nasdaq
- Market Cap
- AB 4.5B
- PRAX 4.0B
- IPO Year
- AB 1988
- PRAX 2020
- Fundamental
- Price
- AB $39.65
- PRAX $179.18
- Analyst Decision
- AB Hold
- PRAX Strong Buy
- Analyst Count
- AB 5
- PRAX 12
- Target Price
- AB $41.00
- PRAX $212.42
- AVG Volume (30 Days)
- AB 165.7K
- PRAX 978.5K
- Earning Date
- AB 10-23-2025
- PRAX 11-05-2025
- Dividend Yield
- AB 8.21%
- PRAX N/A
- EPS Growth
- AB N/A
- PRAX N/A
- EPS
- AB 3.03
- PRAX N/A
- Revenue
- AB N/A
- PRAX $7,463,000.00
- Revenue This Year
- AB N/A
- PRAX N/A
- Revenue Next Year
- AB $8.36
- PRAX $44.43
- P/E Ratio
- AB $13.09
- PRAX N/A
- Revenue Growth
- AB N/A
- PRAX 364.98
- 52 Week Low
- AB $32.28
- PRAX $26.70
- 52 Week High
- AB $43.30
- PRAX $206.71
- Technical
- Relative Strength Index (RSI)
- AB 52.96
- PRAX 62.04
- Support Level
- AB $39.01
- PRAX $159.74
- Resistance Level
- AB $39.87
- PRAX $188.53
- Average True Range (ATR)
- AB 0.59
- PRAX 13.41
- MACD
- AB -0.04
- PRAX -5.00
- Stochastic Oscillator
- AB 38.42
- PRAX 47.30
About AB AllianceBernstein Holding L.P.
AllianceBernstein provides investment management services to institutional (41% of assets under management), retail (42%), and private (17%) clients through products that includes mutual funds, hedge funds, and separately managed accounts. At the end of June 2025, the company had $829 billion in managed assets, composed primarily of fixed-income (37% of AUM) and equity (41%) strategies, with other investments (made up of asset allocation services and certain other alternative investments) accounting for the remainder.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.